LT3466432T - Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti - Google Patents

Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti

Info

Publication number
LT3466432T
LT3466432T LTEP18203799.4T LT18203799T LT3466432T LT 3466432 T LT3466432 T LT 3466432T LT 18203799 T LT18203799 T LT 18203799T LT 3466432 T LT3466432 T LT 3466432T
Authority
LT
Lithuania
Prior art keywords
methods
treating pulmonary
mycobacterial infections
tuberculous mycobacterial
pulmonary non
Prior art date
Application number
LTEP18203799.4T
Other languages
English (en)
Lithuanian (lt)
Inventor
Gina EAGLE
Renu Gupta
Original Assignee
Insmed Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Incorporated filed Critical Insmed Incorporated
Publication of LT3466432T publication Critical patent/LT3466432T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
LTEP18203799.4T 2014-05-15 2015-05-15 Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti LT3466432T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461993439P 2014-05-15 2014-05-15
US201462042126P 2014-08-26 2014-08-26
US201462048068P 2014-09-09 2014-09-09
US201462056296P 2014-09-26 2014-09-26

Publications (1)

Publication Number Publication Date
LT3466432T true LT3466432T (lt) 2020-12-28

Family

ID=54480776

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP18203799.4T LT3466432T (lt) 2014-05-15 2015-05-15 Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
LT15791964T LT3142643T (lt) 2014-05-15 2015-05-15 Būdai, skirti ne tuberkuliozinės mikobakterinės plaučių infekcijos gydymui

Family Applications After (1)

Application Number Title Priority Date Filing Date
LT15791964T LT3142643T (lt) 2014-05-15 2015-05-15 Būdai, skirti ne tuberkuliozinės mikobakterinės plaučių infekcijos gydymui

Country Status (23)

Country Link
US (16) US9895385B2 (enExample)
EP (5) EP4122470B1 (enExample)
JP (5) JP6646653B2 (enExample)
KR (4) KR102447412B1 (enExample)
CN (1) CN106535877A (enExample)
AU (2) AU2015258947B2 (enExample)
BR (1) BR112016026699B1 (enExample)
CA (1) CA2949078C (enExample)
CY (2) CY1122129T1 (enExample)
DK (2) DK3142643T3 (enExample)
ES (4) ES2755941T3 (enExample)
HR (1) HRP20191805T1 (enExample)
HU (1) HUE051440T2 (enExample)
LT (2) LT3466432T (enExample)
ME (1) ME03536B (enExample)
MX (2) MX376012B (enExample)
NZ (1) NZ726256A (enExample)
PL (2) PL3142643T3 (enExample)
PT (2) PT3142643T (enExample)
RS (1) RS60827B1 (enExample)
SI (2) SI3466432T1 (enExample)
SM (1) SMT202000516T1 (enExample)
WO (1) WO2015175939A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3067046B1 (en) 2005-12-08 2020-03-25 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
NO2699580T3 (enExample) 2014-01-24 2018-02-24
CN106535877A (zh) 2014-05-15 2017-03-22 英斯梅德股份有限公司 用于治疗肺部非结核性分枝杆菌感染的方法
KR20240091302A (ko) * 2016-07-29 2024-06-21 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
US20210007985A1 (en) * 2017-04-05 2021-01-14 Aradigm Corporation Liposomal anti-infective formulations to inhibit non-tuberculous mycobacteria (ntm) microaggregate formation and establishment of ntm biofilm
MX2020004110A (es) * 2017-10-16 2020-11-06 Drugrecure Aps Factor estimulante de colonias de granulocito-macrofago (gm-csf) para tratar infecciones refractarias por micobacterias no tuberculosas.
CN108310393A (zh) * 2018-02-12 2018-07-24 丹诺医药(苏州）有限公司 一种利福霉素-喹嗪酮偶联分子的应用
PL3758708T3 (pl) 2018-03-01 2025-03-31 Astrazeneca Ab Kompozycje farmaceutyczne zawierające (2s)-{(1s)-1-cyjano-2-[4-(3-metylo-2-okso-2,3-dihydro-1,3-benzoksazol-5-ilo)fenylo]etylo}-1,4-oksazepano-2-karboksyamid
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
US10736847B2 (en) 2018-07-03 2020-08-11 Becton, Dickinson And Company Inverting device for liposome preparation by centrifugation
US11998553B2 (en) 2018-07-17 2024-06-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
WO2020141478A1 (en) * 2019-01-05 2020-07-09 Foundation For Neglected Disease Research Thiazolyl peptides for the treatment nontuberculous mycobacterial infections
JP2022516671A (ja) * 2019-01-09 2022-03-01 ヤンセン ファーマシューティカ エヌ．ベー． 非結核性抗酸菌症の処置における組合せ
KR20220097447A (ko) * 2019-11-06 2022-07-07 맨카인드 코포레이션 클로파지민의 조성물, 이를 포함하는 조합물, 이의 제조 방법, 이를 포함하는 용도 및 치료 방법
KR102275997B1 (ko) * 2019-11-07 2021-07-13 연세대학교 산학협력단 숙주지향치료를 위한 조성물
US11808135B2 (en) 2020-01-16 2023-11-07 Halliburton Energy Services, Inc. Systems and methods to perform a downhole inspection in real-time
KR20220022877A (ko) * 2020-08-19 2022-02-28 주식회사 미토이뮨테라퓨틱스 Ｍabc-R 감염에 의한 병적 염증 치료제로서의 미토콘드리아 표적 항산화제
US20230263814A1 (en) * 2020-08-31 2023-08-24 Insmed Incorporated Methods for treating newly diagnosed mycobacterium avium complex lung infections
US20250082570A1 (en) * 2021-03-24 2025-03-13 Insmed Incorporated Combination therapy for treating non-tuberculous mycobacterial lung disease
US20240139148A1 (en) * 2021-06-11 2024-05-02 Colorado State University Research Foundation Compositions and methods for treating non-tuberculous mycobacterial infections
KR102615869B1 (ko) * 2021-11-05 2023-12-21 연세대학교 산학협력단 마이코박테리움 아비움 복합체 폐질환 환자의 정보에 따른 치료 반응 예측용 지질대사체 마커
KR102596057B1 (ko) * 2021-11-05 2023-11-01 연세대학교 산학협력단 마이코박테리움 아비움 복합체 감염질환 진단용 지질대사체 마커
WO2023080663A1 (ko) * 2021-11-05 2023-05-11 연세대학교 산학협력단 마이코박테리움 아비움 복합체 감염질환 진단 또는 중증도 예측용 대사체 마커
KR102613631B1 (ko) * 2021-11-05 2023-12-15 연세대학교 산학협력단 마이코박테리움 아비움 복합체 감염증의 중증도 예측용 대사체 마커
WO2023107923A1 (en) * 2021-12-07 2023-06-15 An2 Therapeutics, Inc. Combinations
IL321931A (en) 2023-01-06 2025-09-01 Insmed Inc New and reversible DPP1 inhibitors and their uses
CN121002722A (zh) 2023-09-27 2025-11-21 株式会社Lg新能源 用于去除电解液的设备

Family Cites Families (367)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3006698A (en) 1959-11-25 1961-10-31 Gen Motors Corp Bearing assembly
US3061303A (en) 1961-02-21 1962-10-30 Didde Glaser Inc Self-centering parallel guide assembly
US3091572A (en) 1962-07-16 1963-05-28 Schering Corp Gentamycin and method of production
US3136704A (en) 1962-12-05 1964-06-09 Schering Corp Manufacture of gentamycin
US3852557A (en) 1973-07-12 1974-12-03 Cutler Hammer Inc Electric switch with pivoting and wiping movable contractor
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
HU184141B (en) 1979-12-27 1984-07-30 Human Oltoanyagtermelo Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof
US4451447A (en) 1980-03-31 1984-05-29 Bristol-Myers Company Pharmaceutical formulations
DE3269611D1 (en) 1981-07-02 1986-04-10 Hoffmann La Roche Process for preparing liposome solutions
US4547490A (en) 1981-12-31 1985-10-15 Neomed, Inc. Synthetic whole blood and a method of making the same
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4684625A (en) 1982-07-08 1987-08-04 Syntex (U.S.A.) Inc. Method for enhancing the anti-infective activity of muramyldipeptide derivatives
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4981692A (en) 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
CA1237670A (en) 1983-05-26 1988-06-07 Andrew S. Janoff Drug preparations of reduced toxicity
US4606939A (en) 1983-06-22 1986-08-19 The Ohio State University Research Foundation Small particle formation
CA1237671A (en) 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
GB8322178D0 (en) 1983-08-17 1983-09-21 Sterwin Ag Preparing aerosol compositions
WO1985000968A1 (en) 1983-09-06 1985-03-14 Health Research, Inc. Liposome delivery method for decreasing the toxicity of an antitumor drug
US4721612A (en) 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
SE8403905D0 (sv) 1984-07-30 1984-07-30 Draco Ab Liposomes and steroid esters
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
AU587472B2 (en) 1985-05-22 1989-08-17 Liposome Technology, Inc. Liposome inhalation method and system
US5409704A (en) 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
DE3689769T2 (de) 1985-07-05 1994-07-21 Liposome Co Inc Multilamellare liposome mit verbesserter einschliessungswirkung.
JPH0665648B2 (ja) 1985-09-25 1994-08-24 塩野義製薬株式会社 白金系抗癌物質の安定な凍結真空乾燥製剤
US4861580A (en) 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
US5041278A (en) 1985-10-15 1991-08-20 The Liposome Company, Inc. Alpha tocopherol-based vesicles
US5041581A (en) 1985-10-18 1991-08-20 The University Of Texas System Board Of Regents Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5023087A (en) 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
US4833134A (en) 1986-08-19 1989-05-23 Takeda Chemical Industries, Ltd. Cephem compounds
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US4933121A (en) 1986-12-10 1990-06-12 Ciba Corning Diagnostics Corp. Process for forming liposomes
US5320906A (en) 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
EP0498471B1 (en) 1986-12-23 1996-08-14 The Liposome Company, Inc. Liposomes comprising a guanidino aminoglycoside
US5723147A (en) 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
EP0394265B1 (en) 1987-07-29 1994-11-02 The Liposome Company, Inc. Method for size separation of particles
US4857311A (en) 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US4895452A (en) 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
MX9203504A (es) 1988-04-20 1992-07-01 Liposome Co Inc Complejo agente: lipido activo de alta proporcion.
US5269979A (en) 1988-06-08 1993-12-14 Fountain Pharmaceuticals, Inc. Method for making solvent dilution microcarriers
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
BE1001869A3 (fr) 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
US4952405A (en) * 1988-10-20 1990-08-28 Liposome Technology, Inc. Method of treating M. avium infection
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5843473A (en) 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
WO1991009616A1 (en) 1989-12-22 1991-07-11 Yale University Quinolone antibiotics encapsulated in lipid vesicles
US5820848A (en) 1990-01-12 1998-10-13 The Liposome Company, Inc. Methods of preparing interdigitation-fusion liposomes and gels which encapsulate a bioactive agent
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0527940A1 (en) 1990-05-08 1993-02-24 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
US6623671B2 (en) 1990-10-05 2003-09-23 Royden M. Coe Liposome extrusion process
US5614216A (en) 1990-10-17 1997-03-25 The Liposome Company, Inc. Synthetic lung surfactant
IT1245761B (it) 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
JP3407072B2 (ja) 1991-02-14 2003-05-19 バクスター、インターナショナル、インコーポレイテッド リポソームへの認識物質の結合
US5228346A (en) 1991-04-08 1993-07-20 Marathon Oil Company Method of determining gas flow volume
US6629646B1 (en) 1991-04-24 2003-10-07 Aerogen, Inc. Droplet ejector with oscillating tapered aperture
DE59108798D1 (de) 1991-11-07 1997-08-28 Ritzau Pari Werk Gmbh Paul Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
US5770563A (en) 1991-12-06 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0625207A1 (en) 1991-12-17 1994-11-23 The Regents Of The University Of California Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
US6890555B1 (en) 1992-02-05 2005-05-10 Qlt, Inc. Liposome compositions of porphyrin photosensitizers
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5871710A (en) 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
AU3244393A (en) 1992-12-02 1994-06-22 Vestar, Inc. Antibiotic formulation and process
US5958449A (en) 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
ZA938381B (en) 1993-03-22 1994-06-13 Inland Steel Co Apparatus and method for magnetically confining molten metal using concentrating fins
CA2159596C (en) 1993-04-02 2002-06-11 Royden Coe Method of producing liposomes
CA2120197A1 (en) 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
US5759571A (en) 1993-05-11 1998-06-02 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for drug resistant infections
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
JPH06345663A (ja) 1993-06-08 1994-12-20 Sumitomo Pharmaceut Co Ltd バンコマイシン含有リポソーム製剤
ES2154680T3 (es) 1993-07-08 2001-04-16 Liposome Co Inc Metodo para controlar el tamaño de los liposomas.
CA2101241C (en) 1993-07-23 1998-12-22 Jonathan P. Wong Liposome-encapsulated ciprofloxacin
EP0678017B1 (en) 1993-11-05 1998-04-01 Amgen Inc. Liposome preparation and material encapsulation method
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
JPH09506866A (ja) 1993-12-14 1997-07-08 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 医薬として活性のある物質の免疫療法のための放出制御
ATE168289T1 (de) 1993-12-17 1998-08-15 Pari Gmbh Zerstäuberdüse
AU710504B2 (en) 1994-03-15 1999-09-23 Brown University Research Foundation Polymeric gene delivery system
US5610198A (en) 1994-03-18 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases
EP0682955B1 (de) 1994-05-19 2001-09-05 PARI GmbH Spezialisten für effektive Inhalation Vorrichtung zur Trocknung und Pufferung von Aerosolen
US5550109A (en) 1994-05-24 1996-08-27 Magainin Pharmaceuticals Inc. Inducible defensin peptide from mammalian epithelia
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5993850A (en) 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6000394A (en) 1994-10-26 1999-12-14 Paul Rizau Pari-Werk Gmbh Generation of an aerosol of an exact dose
SA95160463B1 (ar) 1994-12-22 2005-10-04 استرا أكتيبولاج مساحيق للاستنشاق
US5662929A (en) 1994-12-23 1997-09-02 Universite De Montreal Therapeutic liposomal formulation
US5883074A (en) 1995-02-08 1999-03-16 Microcide Pharmaceuticals, Inc. Potentiators of antibacterial agents
US5972379A (en) 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE69632859T2 (de) 1995-04-18 2005-07-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Verfahren zur Arzneistoffbehandlung von Liposomen Zusammensetzung
US5855610A (en) 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
EP0833613A1 (en) 1995-05-26 1998-04-08 Somatix Therapy Corporation Delivery vehicles comprising stable lipid/nucleic acid complexes
ES2173287T3 (es) 1995-06-06 2002-10-16 Bayer Ag Composiciones oticas antibacterianas no irritantes, no sensibilizantes y no ototoxicas.
DE19520622C2 (de) 1995-06-06 2003-05-15 Pari Gmbh Vorrichtung zum Vernebeln von Fluiden
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
CA2224253A1 (en) 1995-06-09 1996-12-27 Martin J. Macphee Chitin hydrogels, methods of their production and use
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
WO1997014740A1 (en) 1995-10-19 1997-04-24 Receptagen Corporation Discrete-length polyethylene glycols
DE19602628C2 (de) 1996-01-25 2000-06-29 Pari Gmbh Vernebler
GB9602969D0 (en) 1996-02-13 1996-04-10 The Technology Partnership Plc Liquid supply apparatus
US5840702A (en) 1996-03-22 1998-11-24 Uab Research Foundation Cystic fibrosis treatment
JP2001521486A (ja) 1996-03-28 2001-11-06 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 改良リポソーム組成物を製造するための材料および方法
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US6132765A (en) 1996-04-12 2000-10-17 Uroteq Inc. Drug delivery via therapeutic hydrogels
CA2174803C (en) 1996-04-23 2000-07-11 Jonathan P. Wong Use of liposome encapsulated ciprofloxacin as an immunotherapeutic drug
DE19616573C2 (de) 1996-04-25 1999-03-04 Pari Gmbh Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase
DE69722793T2 (de) 1996-04-26 2004-05-19 Genaera Corp. Squalamin in kombination mit anderen antikrebs-mittelen zur behandlung von tumoren
GB9609779D0 (en) 1996-05-10 1996-07-17 Univ Bruxelles Freeze dried liposome encapsulated amphiphilic drug compositions and a process for the preparation thereof
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
EP0929293B1 (en) 1996-08-23 2003-10-22 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6451784B1 (en) 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
NZ336381A (en) 1996-12-30 2000-11-24 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
DE19713636A1 (de) 1997-04-02 1998-10-08 Pari Gmbh Atemzugsimulator
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US5957339A (en) 1997-06-23 1999-09-28 Keystone Manufacturing Co., Inc. Water filtration system
JP4142149B2 (ja) 1997-07-10 2008-08-27 明治製菓株式会社 バンコマイシンの凍結乾燥製剤
DE19734022C2 (de) 1997-08-06 2000-06-21 Pari Gmbh Inhalationstherapiegerät mit einem Ventil zur Begrenzung des Inspirationsflusses
US6106858A (en) 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
CA2215716C (en) 1997-09-17 1999-12-07 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Aerosol delivery of liposome-encapsulated fluoroquinolone
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6291500B2 (en) 1997-10-22 2001-09-18 Jens Ponikau Methods and materials for treating and preventing inflammation of mucosal tissue
US20020039596A1 (en) 1997-11-14 2002-04-04 Hartoun Hartounian Production of multivesicular liposomes
US6051251A (en) 1997-11-20 2000-04-18 Alza Corporation Liposome loading method using a boronic acid compound
AU1656799A (en) 1997-12-12 1999-07-05 Inex Pharmaceuticals Corp. Cationic drugs encapsulated in anionic liposomes
GB9827370D0 (en) 1998-01-16 1999-02-03 Pari Gmbh Mouthpiece for inhalation therapy units
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
DE29923847U1 (de) 1998-05-27 2001-04-12 Euroceltique S.A., Luxemburg/Luxembourg Präparate zur Anwendung von entzündungshemmenden, insbesondere antiseptischen Wirkstoffen und/oder die Wundheilung fördernden Wirkstoffen in den unteren Atemwegen
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
DE19827228C2 (de) 1998-06-18 2000-07-13 Pari Gmbh Flüssigkeitszerstäubervorrichtung
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
ES2284266T3 (es) 1998-08-12 2007-11-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Composiciones terapeuticas liposomicas que se pueden obtener mediante el uso de un grandiente de sulfato amonico.
DE19846382C1 (de) 1998-10-08 2000-07-06 Pari Gmbh Zählwerk und seine Verwendung in Inhalatoren, Verneblern oder ähnlichen Dosieraerosolvorrichtungen
CZ20011581A3 (cs) 1998-11-12 2001-12-12 Frank G. Pilkiewicz Systém pro podávání bioaktivní sloučeniny inhalací
US6855296B1 (en) 1998-11-13 2005-02-15 Optime Therapeutics, Inc. Method and apparatus for liposome production
IL143104A (en) 1998-11-13 2005-09-25 Optime Therapeutics Inc Method and apparatus for liposome production
CN1348377A (zh) * 1998-12-17 2002-05-08 希龙公司 用气溶胶化的抗生素治疗严重慢性支气管炎(支气管扩张症)的方法
US6211162B1 (en) 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
WO2000045791A2 (en) 1999-02-08 2000-08-10 Alza Corporation Method for controlling liposome size
WO2000059528A1 (en) 1999-04-02 2000-10-12 The Trustees Of Princeton University Desleucyl glycopeptide antibiotics and methods of making same
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US7297344B1 (en) 1999-05-27 2007-11-20 Euro-Celtique, S.A. Preparations for the promotion of wound healing in the upper respiratory tract and/or ear
JP2003503313A (ja) 1999-06-03 2003-01-28 ジェシー エル エス オウ 細胞増殖及び細胞死を変調する方法及び組成物
CA2376849C (en) 1999-06-24 2008-10-14 Kyowa Hakko Kogyo Co., Ltd. Method of inhibiting leakage of drug encapsulated in liposomes
CA2378438C (en) 1999-07-15 2010-05-04 Inex Pharmaceuticals Corp. Methods for preparation of lipid-encapsulated therapeutic agents
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
US6235177B1 (en) 1999-09-09 2001-05-22 Aerogen, Inc. Method for the construction of an aperture plate for dispensing liquid droplets
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
JP4198850B2 (ja) 1999-11-29 2008-12-17 オムロンヘルスケア株式会社 液体噴霧装置
AU777338B2 (en) 1999-12-04 2004-10-14 Research Development Foundation Carbon dioxide enhancement of inhalation therapy
DE10004465A1 (de) 2000-02-02 2001-08-16 Pari Gmbh Inhalationsvernebler
WO2001056548A2 (en) 2000-02-04 2001-08-09 Lipoxen Technologies Limited Liposomes composition produced by a dehydration-rehydration process
US6761877B2 (en) 2000-02-18 2004-07-13 Biocrystal, Ltd. Functionalized encapsulated fluorescent nanocrystals
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
US7100600B2 (en) 2001-03-20 2006-09-05 Aerogen, Inc. Fluid filled ampoules and methods for their use in aerosolizers
US7971588B2 (en) 2000-05-05 2011-07-05 Novartis Ag Methods and systems for operating an aerosol generator
US8336545B2 (en) 2000-05-05 2012-12-25 Novartis Pharma Ag Methods and systems for operating an aerosol generator
US7600511B2 (en) 2001-11-01 2009-10-13 Novartis Pharma Ag Apparatus and methods for delivery of medicament to a respiratory system
US6948491B2 (en) 2001-03-20 2005-09-27 Aerogen, Inc. Convertible fluid feed system with comformable reservoir and methods
US6968840B2 (en) 2000-05-05 2005-11-29 Aerogen, Inc. Methods and systems for operating an aerosol generator
MXPA02010884A (es) 2000-05-05 2003-03-27 Aerogen Ireland Ltd Aparato y metodo para el suministro de medicamentos al sistema respiratorio.
CA2410577A1 (en) 2000-05-23 2001-12-13 The Trustees Of Columbia University In The City Of New York Method for treating respiratory disorders associated with pulmonary elastic fiber injury
US6338859B1 (en) 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
US6521736B2 (en) 2000-09-15 2003-02-18 University Of Massachusetts Amphiphilic polymeric materials
AU2002214649A1 (en) 2000-10-16 2002-04-29 Neopharm, Inc. Liposomal formulation of mitoxantrone
CN1116875C (zh) 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
US6497901B1 (en) 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
EP1203614A1 (de) 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln
EP1343476B1 (en) 2000-12-01 2008-05-28 Biomira Inc. Preparation of large liposomes by infusion into peg
DE10102846B4 (de) 2001-01-23 2012-04-12 Pari Pharma Gmbh Aerosolgenerator
WO2002060412A2 (en) 2001-02-01 2002-08-08 Board Of Regents Stabilised polymeric aerosols for pulmonary gene delivery
DE10109897A1 (de) 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
US6546927B2 (en) 2001-03-13 2003-04-15 Aerogen, Inc. Methods and apparatus for controlling piezoelectric vibration
JP2002318193A (ja) 2001-04-24 2002-10-31 Canon Inc ネブライザ及び高周波誘導結合プラズマ発光分析装置
US6554201B2 (en) 2001-05-02 2003-04-29 Aerogen, Inc. Insert molded aerosol generator and methods
US6732944B2 (en) 2001-05-02 2004-05-11 Aerogen, Inc. Base isolated nebulizing device and methods
DK1320355T3 (da) 2001-05-18 2006-07-31 Chiron Corp System til administration af en tobramycinformulering
US20030060451A1 (en) 2001-05-29 2003-03-27 Rajneesh Taneja Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
DE10126807C2 (de) 2001-06-01 2003-12-04 Pari Gmbh Inhalationstherapiegerät mit einem Ventil zur Begrenzung des Inspirationsflusses
DE10126808C1 (de) 2001-06-01 2002-08-14 Pari Gmbh Inhalationsmaske
EP1269993A1 (en) 2001-06-21 2003-01-02 Applied NanoSystems B.V. Delivery of small hydrophilic molecules packaged into lipid vesicles
US6991809B2 (en) 2001-06-23 2006-01-31 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
AU2002323151A1 (en) 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
WO2003015707A2 (en) 2001-08-20 2003-02-27 Transave, Inc. Method for treating lung cancers
US6623723B2 (en) * 2001-08-21 2003-09-23 Cellular Sciences Inc. Method for treating bronchial constriction and bronchospasm
KR20040032942A (ko) * 2001-08-21 2004-04-17 화이자 프로덕츠 인코포레이티드 호흡기 감염증을 치료하기 위한 일회분량의 아지트로마이신
EP1304130B1 (de) 2001-10-18 2004-06-23 PARI GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
EP1304131B1 (de) 2001-10-18 2005-06-29 PARI GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
WO2003035876A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Verwendung einer doppelsträngigen ribonukleinsäure zur behandlung einer infektion mit einem (+)-strang-rna-virus
US20030096774A1 (en) 2001-11-21 2003-05-22 Igor Gonda Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
JP4669224B2 (ja) 2002-01-15 2011-04-13 エアロジェン，インコーポレイテッド 有効解剖学的死腔からのエアロゾルを浄化するためのシステムおよび方法
US20040009126A1 (en) 2002-03-05 2004-01-15 Transave, Inc. Inhalation system for prevention and treatment of intracellular infections
US20030205226A1 (en) 2002-05-02 2003-11-06 Pre Holding, Inc. Aerosol medication inhalation system
WO2003097126A2 (en) 2002-05-20 2003-11-27 Aerogen, Inc. Aerosol for medical treatment and methods
ATE485031T1 (de) 2002-06-28 2010-11-15 Protiva Biotherapeutics Inc Verfahren und vorrichtung zur herstellung von liposomen
EP1386672B1 (en) 2002-08-02 2010-04-07 PARI Pharma GmbH Fluid droplet production apparatus
AU2003302314A1 (en) 2002-08-02 2004-07-09 Transave, Inc. Platinum aggregates and process for producing the same
AU2003268087A1 (en) 2002-08-23 2004-03-11 Ian Ma Liposomal gemcitabine compositions for better drug delivery
DE10239321B3 (de) 2002-08-27 2004-04-08 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
KR100489701B1 (ko) 2002-10-09 2005-05-16 주식회사 태평양 고농도의 트리터페노이드를 함유하는 미소화 리포좀 및 그제조방법
US20230008563A1 (en) 2002-10-29 2023-01-12 Insmed Incorporated Sustained release of antiinfectives
US7879351B2 (en) 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
JP5118302B2 (ja) 2002-10-29 2013-01-16 トランセイブ， インク． 抗感染剤の徐放
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
DE10250625A1 (de) 2002-10-30 2004-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
US20040170677A1 (en) 2002-11-26 2004-09-02 Ning Hu Method of drug loading in liposomes by gradient
DE10257381B4 (de) 2002-12-09 2006-09-14 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
WO2004071466A2 (en) 2003-02-11 2004-08-26 Neopharm, Inc. Manufacturing process for liposomal preparations
JP2006515227A (ja) 2003-02-24 2006-05-25 ジーティーシー バイオセラピューティックス インコーポレイテッド 十字流濾過の方法およびそのための装置
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
US6900184B2 (en) 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
DE10320143A1 (de) 2003-05-06 2004-12-16 Pari GmbH Spezialisten für effektive Inhalation Vernebleranschlussvorrichtung für Beatmungsgeräte oder dergleichen
DE10322505B4 (de) 2003-05-19 2009-11-05 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapiemaske und -vorrichtung für Tiere
US8058493B2 (en) 2003-05-21 2011-11-15 Baker Hughes Incorporated Removing amines from hydrocarbon streams
US20050025822A1 (en) 2003-05-30 2005-02-03 Wong Frances M.P. Method of pulmonary administration of an agent
US8616195B2 (en) 2003-07-18 2013-12-31 Novartis Ag Nebuliser for the production of aerosolized medication
AU2004267317A1 (en) 2003-08-20 2005-03-03 Eisai R&D Management Co., Ltd. Method of detecting effect of controlling synoviolin activity
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
DE10345950A1 (de) 2003-10-02 2005-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit Ventil
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
DE10348237A1 (de) 2003-10-16 2005-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit einem Düsenvernebler
US20050214224A1 (en) 2003-11-04 2005-09-29 Nektar Therapeutics Lipid formulations for spontaneous drug encapsulation
DE602004005564T2 (de) 2003-12-31 2007-12-13 Orthologic Corp., Tempe Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten
US7452524B2 (en) 2004-01-27 2008-11-18 Gilead Sciences, Inc. Method for improvement of tolerance for therapeutically effective agents delivered by inhalation
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
DE102004016985B4 (de) 2004-04-07 2010-07-22 Pari Pharma Gmbh Aerosolerzeugungsvorrichtung und Inhalationsvorrichtung
JP4452799B2 (ja) 2004-07-14 2010-04-21 独立行政法人産業技術総合研究所 コアセルベートを活用したリポソームの製造方法
CA2584583A1 (en) 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
AU2005306533B2 (en) 2004-11-17 2012-05-31 Arbutus Biopharma Corporation siRNA silencing of apolipoprotein B
US8337815B2 (en) 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
DE102005006374B3 (de) 2005-02-11 2006-07-20 Pari GmbH Spezialisten für effektive Inhalation Aerosolerzeugungsvorrichtung und Inhalationstherapiegerät mit einer derartigen Vorrichtung
DE102005006375B4 (de) 2005-02-11 2007-10-11 Pari GmbH Spezialisten für effektive Inhalation Aerosolerzeugungsvorrichtung für Inhalationstherapiegeräte
DE102005006372B4 (de) 2005-02-11 2007-11-29 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung und Verfahren zu deren Betrieb
US20060198940A1 (en) 2005-03-04 2006-09-07 Mcmorrow David Method of producing particles utilizing a vibrating mesh nebulizer for coating a medical appliance, a system for producing particles, and a medical appliance
JP2006263054A (ja) 2005-03-23 2006-10-05 Konica Minolta Sensing Inc 呼吸器系疾患関連解析データの取得方法、オキシメータシステム及びその動作プログラム、オキシメータ並びに酸素補給システム
EP1712220A1 (en) 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
AU2006249574B2 (en) 2005-05-25 2012-01-19 Novartis Ag Vibration systems and methods
DE102005024779B4 (de) 2005-05-31 2008-02-21 Pari GmbH Spezialisten für effektive Inhalation Atemzuggesteuerte Inhalationstherapievorrichtung
DE102005029498B4 (de) 2005-06-24 2007-08-30 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
USD656604S1 (en) 2005-06-28 2012-03-27 Pari Gmbh Part for inhalation therapy nebuliser
DE102005034403B3 (de) 2005-07-22 2007-02-22 Airbus Deutschland Gmbh Führungsmittel für eine Vorrichtung zur Herstellung von Faservorformlingen im TFP-Verfahren für Verbundbauteile
EP1937213B1 (en) 2005-07-27 2017-10-25 Protiva Biotherapeutics Inc. Systems and methods for manufacturing liposomes
DE602006014695D1 (de) 2005-08-31 2010-07-15 Toray Industries Mehrlagige polymilchsäureharzfolie und daraus geformter körper
ATE439802T1 (de) 2005-09-07 2009-09-15 Koninkl Philips Electronics Nv System und verfahren zum induktiven messen der bioimpedanz eines leitfähigen gewebes
US20070065367A1 (en) * 2005-09-20 2007-03-22 Rany Condos Method of treating pulmonary disease with interferons
KR100705981B1 (ko) 2005-10-12 2007-04-10 주식회사 리제론 인간 성장호르몬을 포함하는 탈모방지 또는 발모촉진용조성물
US20070105758A1 (en) 2005-10-31 2007-05-10 May Thomas B Vancomycin formulations having reduced amount of histamine
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
EP3067046B1 (en) 2005-12-08 2020-03-25 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
DE102006001113B3 (de) 2006-01-09 2007-06-28 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
US8263645B2 (en) 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
DE102006006183A1 (de) 2006-02-10 2007-08-16 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung für die Anwendung bei Frühgeborenen und Kleinkindern
US7958887B2 (en) 2006-03-10 2011-06-14 Aradigm Corporation Nozzle pore configuration for intrapulmonary delivery of aerosolized formulations
DE102006012174A1 (de) 2006-03-16 2007-09-20 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapiegerätekompressor
WO2007117550A2 (en) 2006-04-06 2007-10-18 Transave, Inc. Methods for coacervation induced liposomal encapsulation and formulations thereof
DE102006017002B3 (de) 2006-04-11 2007-01-11 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit mehrfachen Düsen
USD583928S1 (en) 2006-04-27 2008-12-30 Pari Pharama Gmbh Nebulizer
US20080131497A1 (en) 2006-09-28 2008-06-05 Perkins Walter R Formulations of DNase and Methods of Use Thereof
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8071127B2 (en) 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8119156B2 (en) 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US20080108104A1 (en) * 2006-11-02 2008-05-08 Colorado State University Research Foundation Identification of bacterial species and subspecies using lipids
EP1927373B1 (en) 2006-11-30 2012-08-22 PARI Pharma GmbH Inhalation nebulizer
CN102648916A (zh) * 2007-02-09 2012-08-29 联合治疗公司 用于间质性肺病和哮喘的曲前列尼治疗
DE502007002037D1 (de) 2007-04-11 2009-12-31 Pari Gmbh Aerosoltherapievorrichtung
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
WO2008137917A1 (en) 2007-05-07 2008-11-13 Transave, Inc. Method of treating bacterial infections with antibacterial formulations
US9333214B2 (en) * 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
UA27298U (en) 2007-06-13 2007-10-25 Method for preventing pleural empyema after pneumonectomy
UA27804U (en) 2007-07-26 2007-11-12 Method for preventing respiratory complications after surgery in lungs and pleura
EP2030644A1 (en) 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
NZ562236A (en) * 2007-10-05 2010-04-30 Univ Otago Detection of volatile compounds as markers for Mycobacteria tuberculosis
AU2008316841B2 (en) 2007-10-23 2014-04-17 Insmed Incorporated Liposomal vancomycin formulations
KR101303180B1 (ko) 2007-11-09 2013-09-09 삼성전자주식회사 수직채널 트랜지스터를 구비한 반도체 메모리 소자 및 그제조 방법
DE102007056462B4 (de) 2007-11-23 2011-10-27 Pari Pharma Gmbh Einwegampulle für eine Vorrichtung zur Erzeugung von Aerosolen
ES2884673T3 (es) 2008-04-08 2021-12-10 Melinta Therapeutics Inc Oritavancina para inhibir y tratar biopelículas
DE102008022987A1 (de) 2008-05-09 2009-11-12 Pari Pharma Gmbh Vernebler für Beatmungsmaschinen und Beatmungsmaschine mit einem solchen Vernebler
EP2743265B1 (en) 2008-10-09 2017-03-15 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010111641A2 (en) 2009-03-26 2010-09-30 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
EP2248517B1 (en) 2009-05-08 2014-03-26 PARI Pharma GmbH Concentrated mast cell stabilizing pharmaceutical formulations
DE102009026636B4 (de) 2009-06-02 2011-04-14 Pari Pharma Gmbh Verfahren zum Verschweißen einer Membran mit einem Träger bei der Herstellung eines Membranverneblers
DK2453864T3 (en) 2009-07-17 2017-01-09 Nektar Therapeutics Systems and methods for operating sealing atomizers
CN102573967B (zh) 2009-07-17 2014-06-11 内克塔医疗公司 负偏压密封的喷雾器系统和方法
CN102472648B (zh) 2009-07-22 2014-04-16 皇家飞利浦电子股份有限公司 具有低响应时间和高灵敏度的热流量传感器集成电路
WO2011038901A1 (en) * 2009-09-29 2011-04-07 Activaero Gmbh Improved method for treatment of patients with cystic fibrosis
WO2011049960A2 (en) 2009-10-21 2011-04-28 Otonomy, Inc. Compositions and methods for the treatment of sinonasal disorders
US8536220B2 (en) 2010-01-26 2013-09-17 Murray Fulgham Supplement composition and method of use
WO2011108955A1 (en) 2010-03-03 2011-09-09 Universidade De Coimbra Multi -targeting system comprising a nanocarrier, nucleic acid(s) and non-nucleic acid based drug(s)
WO2011133617A1 (en) 2010-04-23 2011-10-27 The Board Of Trustees Of The University Of Illinois Nano-hybrid delivery system for sequential utilization of passive and active targeting
CA2801066C (en) 2010-06-02 2021-02-09 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
KR102012418B1 (ko) 2010-07-12 2019-08-20 셀리아 파마슈티칼즈 에이피에스 에어로졸화에 의한 토브라마이신의 투여에 의한 폐 감염의 치료
CN103179951B (zh) 2010-08-20 2016-01-20 雷迪博士实验室有限公司 磷脂储库
JP2013538830A (ja) 2010-09-27 2013-10-17 マイクロドース セラピューテクス，インコーポレイテッド 吸入を用いる疾患治療のための方法及び組成物
CA2812417C (en) 2010-09-29 2019-10-22 Pulmatrix, Inc. Cationic dry powders
EP2457609A1 (en) 2010-11-24 2012-05-30 PARI Pharma GmbH Aerosol generator
DK2670242T3 (da) 2011-01-31 2022-05-02 Avalyn Pharma Inc Aerosolpirfenidon- og pyridonanalogforbindelser og anvendelser deraf
CA2836643C (en) 2011-05-19 2017-11-14 Savara, Inc. Dry powder vancomycin compositions and associated methods
EP4631628A3 (en) 2011-06-08 2025-12-10 PARI Pharma GmbH Aerosol generator
EP2768958B1 (en) 2011-10-18 2019-08-14 Dicerna Pharmaceuticals, Inc. Amine cationic lipids and uses thereof
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
IN2014DN05866A (enExample) 2011-12-22 2015-05-22 Nuvo Res Gmbh
US20130280174A1 (en) 2012-04-20 2013-10-24 The Gillette Company Personal care composition comprising metathesized unsaturated polyol esters
US9925295B2 (en) 2012-05-09 2018-03-27 Amedica Corporation Ceramic and/or glass materials and related methods
EP4331675A3 (en) 2012-05-21 2024-05-29 Insmed Incorporated Systems for treating pulmonary infections
AU2013299641A1 (en) * 2012-08-10 2015-03-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug delivery vehicle comprising conjugates between targeting polyamino acids and fatty acids
WO2014052634A1 (en) 2012-09-27 2014-04-03 The University Of North Carolina At Chapel Hill Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
US9693958B2 (en) 2013-03-15 2017-07-04 Cureport, Inc. Methods and devices for preparation of lipid nanoparticles
WO2015017807A1 (en) 2013-08-01 2015-02-05 University Of Georgia Research Foundation, Inc. Liposomal formulations for the treatment of bacterial infections
US9198359B2 (en) 2013-09-20 2015-12-01 Deere & Company Frame for a reciprocating sieve
MX2016005232A (es) 2013-10-22 2017-01-19 Aradigm Corp Formulaciones liposomicas para inhalacion, modificadas con agente tensoactivo, que proveen un perfil de liberacion tanto inmediata como sostenida.
AU2015244399B2 (en) 2014-04-08 2019-10-03 Aradigm Corporation Liposomes that form drug nanocrystals after freeze-thaw
AU2015244275B2 (en) 2014-04-08 2019-08-29 Aradigm Corporation Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
US20160120806A1 (en) 2014-04-08 2016-05-05 Aradigm Corporation Nanocrystals formed in a microenvironment
CN106535877A (zh) 2014-05-15 2017-03-22 英斯梅德股份有限公司 用于治疗肺部非结核性分枝杆菌感染的方法
SG11201508664VA (en) 2014-08-29 2016-03-30 Emd Millipore Corp Single Pass Tangential Flow Filtration Systems and Tangential Flow Filtration Systems withRecirculation of Retentate
CA2977827C (en) 2015-03-19 2023-10-17 University Of Connecticut Systems and methods for continuous manufacturing of liposomal drug formulations
JP6884714B2 (ja) 2015-07-09 2021-06-09 インスメッド インコーポレイテッド 肺疾患及び肺損傷を治療するための組成物及び方法
JP2019500318A (ja) 2015-11-18 2019-01-10 インスメッド インコーポレイテッド 細菌感染症を治療するための組成物及び方法
GB201600290D0 (en) 2016-01-07 2016-02-24 Fujifilm Diosynth Biotechnologies Uk Ltd Process
US10183108B2 (en) 2016-02-04 2019-01-22 Pall Corporation Inline diafiltration with multi-channel pump
US20190029970A1 (en) 2017-07-31 2019-01-31 The Chinese University Of Hong Kong Fatty acid conjugated nanoparticles and uses thereof
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
US20210113467A1 (en) 2018-05-02 2021-04-22 Robert Worsham Methods for the manufacture of liposomal drug formulations
US20200384007A1 (en) 2019-06-06 2020-12-10 Board Of Regents, The University Of Texas System Lipid nanoparticles containing pharmaceutical and/or nutraceutical agents and methods thereof
JP2024520789A (ja) 2021-06-09 2024-05-24 インスメッド インコーポレイテッド リポソームアミノグリコシド製剤のインビトロ放出アッセイ法

Also Published As

Publication number Publication date
US10751355B2 (en) 2020-08-25
KR20240018675A (ko) 2024-02-13
CA2949078A1 (en) 2015-11-19
MX384843B (es) 2025-03-14
US12168022B2 (en) 2024-12-17
EP3142643B1 (en) 2019-07-10
KR20230015496A (ko) 2023-01-31
US10398719B2 (en) 2019-09-03
CA2949078C (en) 2022-09-20
US20180311267A1 (en) 2018-11-01
AU2015258947A1 (en) 2017-01-12
US20210228606A1 (en) 2021-07-29
JP6892529B2 (ja) 2021-06-23
SMT202000516T1 (it) 2020-11-10
KR102489036B1 (ko) 2023-01-13
US11446318B2 (en) 2022-09-20
MX2020010726A (es) 2021-07-27
US12377114B2 (en) 2025-08-05
HUE051440T2 (hu) 2021-03-01
US20230037417A1 (en) 2023-02-09
KR102657132B1 (ko) 2024-04-12
AU2015258947B2 (en) 2020-04-09
MX376012B (es) 2025-03-07
JP2021143187A (ja) 2021-09-24
CY1123411T1 (el) 2021-12-31
US20250057863A1 (en) 2025-02-20
US12168021B2 (en) 2024-12-17
US20200009171A1 (en) 2020-01-09
US20190160086A1 (en) 2019-05-30
KR102447412B1 (ko) 2022-09-23
EP4393491A2 (en) 2024-07-03
US20200268781A1 (en) 2020-08-27
BR112016026699B1 (pt) 2022-09-13
US20200345754A1 (en) 2020-11-05
PT3142643T (pt) 2019-10-28
SI3466432T1 (sl) 2020-11-30
ES2926985T3 (es) 2022-10-31
DK3142643T3 (da) 2019-10-14
US11395830B2 (en) 2022-07-26
EP3466432A1 (en) 2019-04-10
JP2025122086A (ja) 2025-08-20
JP7212717B2 (ja) 2023-01-25
ES2981634T3 (es) 2024-10-09
US20220395524A1 (en) 2022-12-15
HRP20191805T1 (hr) 2019-12-27
KR20170005104A (ko) 2017-01-11
PL3466432T3 (pl) 2021-02-08
JP2020055877A (ja) 2020-04-09
US10588918B2 (en) 2020-03-17
BR112016026699A2 (pt) 2017-08-15
US20180185401A1 (en) 2018-07-05
RS60827B1 (sr) 2020-10-30
NZ726256A (en) 2022-11-25
AU2020204530A1 (en) 2020-07-30
US10238675B2 (en) 2019-03-26
BR112016026699A8 (pt) 2021-06-29
EP3142643A1 (en) 2017-03-22
SI3142643T1 (sl) 2019-11-29
US20240366643A1 (en) 2024-11-07
EP4122470B1 (en) 2024-03-20
EP3766501B1 (en) 2022-07-06
DK3466432T3 (da) 2020-09-28
US20250325574A1 (en) 2025-10-23
ME03536B (me) 2020-04-20
US20170360816A1 (en) 2017-12-21
MX2016014921A (es) 2017-07-28
ES2820226T3 (es) 2021-04-20
US20190216834A1 (en) 2019-07-18
JP7686017B2 (ja) 2025-05-30
EP3142643A4 (en) 2018-01-10
JP2017515913A (ja) 2017-06-15
EP4393491A3 (en) 2024-07-24
ES2755941T3 (es) 2020-04-24
JP6646653B2 (ja) 2020-02-14
US20150328244A1 (en) 2015-11-19
CN106535877A (zh) 2017-03-22
EP3466432B1 (en) 2020-07-08
KR20220136448A (ko) 2022-10-07
US10251900B2 (en) 2019-04-09
CY1122129T1 (el) 2020-11-25
PL3142643T3 (pl) 2019-12-31
LT3142643T (lt) 2019-10-25
PT3466432T (pt) 2020-10-08
AU2020204530B2 (en) 2022-06-23
EP4122470A1 (en) 2023-01-25
US9895385B2 (en) 2018-02-20
US12016873B2 (en) 2024-06-25
WO2015175939A1 (en) 2015-11-19
EP3766501A1 (en) 2021-01-20
US20230330119A1 (en) 2023-10-19
US10828314B2 (en) 2020-11-10
JP2023033417A (ja) 2023-03-10

Similar Documents

Publication Publication Date Title
PT3142643T (pt) Métodos para o tratamento de infeções mico bacterianas pulmonares não tuberculares
SI3785717T1 (sl) Postopki za zdravljenje okužb s Coronaviridae
EP3229808A4 (en) Methods for treating fungal infections
GB201406151D0 (en) Method
GB201408119D0 (en) Method
GB201406155D0 (en) Method
EP3188722A4 (en) Methods for treating protozoan infections
SG10201503996XA (en) Method for processing local information
GB201403470D0 (en) Method
PT3160263T (pt) Composições para prevenção de infeções
IL249616A0 (en) Methods for treating inflammation
GB2531269B (en) Tape application method
GB201407971D0 (en) Method
TH1501004125A (th) สารประกอบและวิธีการสำหรับการรักษาการติดเชื้อแบคทีเรีย
AU2014903503A0 (en) Methods For Treating Protozoan Infections
AU2014902467A0 (en) Methods For Treating Protozoan Infections
TH1601000110A (th) อุปกรณ์ทำให้สมดุล, อุปกรณ์ทำให้สม่ำเสมอ และวิธีการสำหรับใช้สิ่งดังกล่าว
GB201410316D0 (en) Recording method
GB201419758D0 (en) Alice method
GB201407948D0 (en) Method
GB201407815D0 (en) Method
GB201407809D0 (en) Method
GB201406509D0 (en) Method
GB201406398D0 (en) Method
GB201406399D0 (en) Method